William A Beltran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2934884/publications.pdf

Version: 2024-02-01

40 papers 1,517 citations

430874 18 h-index 35 g-index

42 all docs 42 docs citations

times ranked

42

1599 citing authors

#	Article	IF	CITATIONS
1	Altered transsulfuration pathway enzymes and redox homeostasis in inherited retinal degenerative diseases. Experimental Eye Research, 2022, 215, 108902.	2.6	5
2	Targeting ON-bipolar cells by AAV gene therapy stably reverses <i>LRIT3</i> -congenital stationary night blindness. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117038119.	7.1	14
3	Gene therapy reforms photoreceptor structure and restores vision in NPHP5-associated Leber congenital amaurosis. Molecular Therapy, 2021, 29, 2456-2468.	8.2	18
4	Enhancer of Zeste Homolog 2 (EZH2) Contributes to Rod Photoreceptor Death Process in Several Forms of Retinal Degeneration and Its Activity Can Serve as a Biomarker for Therapy Efficacy. International Journal of Molecular Sciences, 2021, 22, 9331.	4.1	5
5	Short prolactin isoforms are expressed in photoreceptors of canine retinas undergoing retinal degeneration. Scientific Reports, 2021, 11, 460.	3.3	3
6	scAAVengr, a transcriptome-based pipeline for quantitative ranking of engineered AAVs with single-cell resolution. ELife, $2021,10,10$	6.0	33
7	Retinal structural and microvascular abnormalities in retinal dysplasia imaged by OCT and OCT angiography. Veterinary Ophthalmology, 2021, , .	1.0	O
8	Characterization of the Canine Retinal Vasculature With Optical Coherence Tomography Angiography: Comparisons With Histology and Fluorescein Angiography. Frontiers in Neuroanatomy, 2021, 15, 785249.	1.7	4
9	Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy. Molecular Therapy, 2020, 28, 266-278.	8.2	56
10	Toxicity and Efficacy Evaluation of an Adeno-Associated Virus Vector Expressing Codon-Optimized <i>RPGR</i> Delivered by Subretinal Injection in a Canine Model of X-linked Retinitis Pigmentosa. Human Gene Therapy, 2020, 31, 253-267.	2.7	22
11	Focal/multifocal and geographic retinal dysplasia in the dog—In vivo retinal microanatomy analyses. Veterinary Ophthalmology, 2020, 23, 292-304.	1.0	9
12	Rod function deficit in retained photoreceptors of patients with class B Rhodopsin mutations. Scientific Reports, 2020, 10, 12552.	3.3	10
13	Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-Linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy. Human Gene Therapy, 2020, 31, 743-755.	2.7	15
14	In-vivo longitudinal changes in thickness of the postnatal canine retina. Experimental Eye Research, 2020, 192, 107926.	2.6	5
15	Progress in Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa. Advances in Experimental Medicine and Biology, 2019, 1185, 113-118.	1.6	15
16	<i>BEST1</i> gene therapy corrects a diffuse retina-wide microdetachment modulated by light exposure. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2839-E2848.	7.1	62
17	Photoreceptor Outer Segment Isolation from a Single Canine Retina for RPE Phagocytosis Assay. Advances in Experimental Medicine and Biology, 2018, 1074, 593-601.	1.6	2
18	Translational Retinal Research and Therapies. Translational Vision Science and Technology, 2018, 7, 8.	2.2	11

#	Article	IF	CITATIONS
19	Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8547-E8556.	7.1	114
20	Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations. Molecular Therapy, 2017, 25, 1866-1880.	8.2	60
21	Involvement of Innate Immune System in Late Stages of Inherited Photoreceptor Degeneration. Scientific Reports, 2017, 7, 17897.	3 . 3	30
22	Acute and Protracted Cell Death in Light-Induced Retinal Degeneration in the Canine Model of Rhodopsin Autosomal Dominant Retinitis Pigmentosa., 2017, 58, 270.		12
23	Overlap of abnormal photoreceptor development and progressive degeneration in Leber congenital amaurosis caused by <i>NPHP5 </i> mutation. Human Molecular Genetics, 2016, 25, 4211-4226.	2.9	35
24	Assessment of visual function and retinal structure following acute light exposure in the light sensitive T4R rhodopsin mutant dog. Experimental Eye Research, 2016, 146, 341-353.	2.6	25
25	Exclusion of the Unfolded Protein Response in Light-Induced Retinal Degeneration in the Canine T4R RHO Model of Autosomal Dominant Retinitis Pigmentosa. PLoS ONE, 2015, 10, e0115723.	2.5	14
26	Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5844-53.	7.1	75
27	Gene Augmentation for X-Linked Retinitis Pigmentosa Caused by Mutations in RPGR. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017392-a017392.	6.2	19
28	Canine Retina Has a Primate Fovea-Like Bouquet of Cone Photoreceptors Which Is Affected by Inherited Macular Degenerations. PLoS ONE, 2014, 9, e90390.	2.5	100
29	Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5574-83.	7.1	104
30	Up-Regulation of Tumor Necrosis Factor Superfamily Genes in Early Phases of Photoreceptor Degeneration. PLoS ONE, 2013, 8, e85408.	2.5	29
31	Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2132-2137.	7.1	237
32	Age-Dependent Disease Expression Determines Remodeling of the Retinal Mosaic in Carriers of RPGRExon ORF15 Mutations., 2009, 50, 3985.		31
33	CREB1/ATF1 Activation in Photoreceptor Degeneration and Protection., 2009, 50, 5355.		14
34	The use of canine models of inherited retinal degeneration to test novel therapeutic approaches. Veterinary Ophthalmology, 2009, 12, 192-204.	1.0	41
35	On the Role of CNTF as a Pontential Therapy for Retinal Degeneration: Dr. Jekyll or Mr. Hyde?. Advances in Experimental Medicine and Biology, 2008, 613, 45-51.	1.6	10
36	Intravitreal injection of ciliary neurotrophic factor (CNTF) causes peripheral remodeling and does not prevent photoreceptor loss in canine RPGR mutant retina. Experimental Eye Research, 2007, 84, 753-771.	2.6	33

3

#	Article	IF	CITATIONS
37	Ocular findings in two colonies of gray mouse lemurs (Microcebus murinus). Veterinary Ophthalmology, 2007, 10, 43-49.	1.0	35
38	A Frameshift Mutation in RPGRExon ORF15 Causes Photoreceptor Degeneration and Inner Retina Remodeling in a Model of X-Linked Retinitis Pigmentosa., 2006, 47, 1669.		115
39	Immunolocalization of ciliary neurotrophic factor receptor alpha (CNTFRalpha) in mammalian photoreceptor cells. Molecular Vision, 2005, 11 , 232-44.	1.1	41
40	Cloning, Mapping, and Retinal Expression of the Canine Ciliary Neurotrophic Factor Receptor α (CNTFRα)., 2003, 44, 3642.		52